DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
LAURUSLABS logo

Laurus Labs Limited Stock Price

NSEI:LAURUSLABS Community·₹1.1t Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 26 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

LAURUSLABS Share Price Performance

₹1,945.00
1049.40 (117.17%)
​
₹1,486.29
Fair Value
₹1,945.00
1049.40 (117.17%)
30.9% overvalued intrinsic discount
₹1,486.29
Fair Value
Price ₹1,945.00
AnalystConsensusTarget ₹1,486.29
AnalystHighTarget ₹1,980.00
AnalystLowTarget ₹657.00
Fri, 14 Aug 26
Fair Value₹1,486.29
Share Pricen/a

LAURUSLABS Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value ₹1.49k 30.9% overvalued intrinsic discount

LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value ₹1.98k 1.8% undervalued intrinsic discount

Digital Transformation And Affordable Generics Will Expand Global Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value ₹657 196.0% overvalued intrinsic discount

Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LAURUSLABS logo
Laurus Labs
196.0% overvalued intrinsic discount

Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
LAURUSLABS logo
Laurus Labs
30.9% overvalued intrinsic discount

LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 14 Aug
Read Narrative
LAURUSLABS logo
Laurus Labs
1.8% undervalued intrinsic discount

Digital Transformation And Affordable Generics Will Expand Global Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 31 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
LAURUSLABS logo

LAURUSLABS: Rich Pricing And Lower Future P/E Will Limit Upside

Fair Value: ₹657 196.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
LAURUSLABS logo

LAURUSLABS: Future Returns Will Depend On Resilient Margins Supporting Elevated P E Multiples

Fair Value: ₹1.49k 30.9% overvalued intrinsic discount
15 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
LAURUSLABS logo

LAURUSLABS: Higher Margin Outlook And Upcoming Results Dates Will Shape Future Appeal

Fair Value: ₹1.98k 1.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

High growth potential with solid track record.

1 Risk
2 Rewards
View Full Analysis

Laurus Labs Limited Key Details

₹72.7b

Revenue

₹29.5b

Cost of Revenue

₹43.2b

Gross Profit

₹32.3b

Other Expenses

₹10.9b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
20.24
59.45%
15.04%
46.4%
View Full Analysis

About LAURUSLABS

Founded
2005
Employees
7059
CEO
Satyanarayana Chava
WebsiteView website
www.lauruslabs.com

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Recent LAURUSLABS News & Updates

User avatar
Narrative Update • Sep 03

LAURUSLABS: Rich Pricing And Lower Future P/E Will Limit Upside

The analyst fair value estimate for Laurus Labs has been updated from ₹540.50 to ₹657.00 as analysts factor in revised assumptions on growth, margins, and valuation multiples informed by recent sector research commentary. Analyst Commentary Recent Street research on education companies offers a useful reference point for how bearish analysts may approach a stock like Laurus Labs when concerns build around valuation, execution, or growth expectations.
User avatar
Narrative Update • Aug 14

LAURUSLABS: Future Returns Will Depend On Resilient Margins Supporting Elevated P E Multiples

The Laurus Labs analyst price target has been updated from ₹1,044.00 to about ₹1,486.29. This change is supported by analyst assumptions that reflect higher revenue growth, stronger profit margins and a modestly higher future P/E, while keeping the discount rate broadly similar.

Recent updates

No updates

Laurus Labs Limited Competitors

SUNPHARMA logo

Sun Pharmaceutical Industries

Symbol: NSEI:SUNPHARMA
Market cap: ₹4.5t
DIVISLAB logo

Divi's Laboratories

Symbol: NSEI:DIVISLAB
Market cap: ₹2.5t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide